Authors : Shravan Subhash; Prasanth Hanumanthu; Moin Akhtar Shaik; Deexitha Mudigonda; Umar Saleem

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/23kpypc7

Scribd : https://tinyurl.com/ukkvcre2

DOI : https://doi.org/10.38124/ijisrt/25jul896

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : The gut-skin axis has become an important conceptual framework to identify a relationship between gut microbiota and skin immunity, particularly in autoimmune dermatologic diseases. This narrative review aims to summarize recent data examining how gut dysbiosis, characterized by low microbial diversity and disruption of each of the gut's microbial communities, plays a role in the pathogenesis and pathophysiology of psoriasis, systemic lupus erythematosus (SLE), alopecia areata, and scleroderma. We consider different pathways, including but not limited to increased intestinal permeability ("leaky gut"), Th17/Treg balance, the presence of and/or development of pro-inflammatory cytokines, and molecular mimicry, for how gut dysbiosis drives immune dysregulation in the skin. Clinical and translational evidence of microbiome-based therapies with probiotics, prebiotics, and fecal microbiota transplantation (FMT) has been shown not only to improve disease severity but also reduce systemic inflammation and restore gut microbiome diversity and community structure. Specific AMR therapies have indicated differences in PASI, SLEDAI, and inflammatory markers such as IL-6 and TNF-α. This narrative review strongly affirms that ambient need for more precision-based solutions to prevent and treat autoimmunity using a combination of multi- omics, gut microbiome profiling, as well as artificial intelligence (AI)-driven individualized solutions. Ultimately, the gut–skin axis depicts autoimmune skin diseases from single dermatologic disease classifications to systemic immune diseases grounded in gut health, offering new possibilities for diagnosis, intervention, and disease modulation.

Keywords : Gut Microbiota; Gut Skin Axis, Immune Modulation; Intestinal Barrier Dysfunction; Psoriasis; SLE; Alopecia Areata; Scleroderma.

References :

1. Sikora M, Stec A, Chrabaszcz M, Knot A, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Gut microbiome in psoriasis: An updated review. Pathogens. 2020;9:463. doi:10.3390/pathogens9060463.
2. Mahmud MR, Akter S, Tamanna SK, Mazumder L, Esti IZ, Banerjee S, Akter S, Hasan MR, Acharjee M, Hossain MS, Pirttilä AM. Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases. Gut Microbes. 2022;14(1):2096995. doi:10.1080/19490976.2022.2096995.
3. Kobayashi T, Naik S, Nagao K. Choreographing immunity in the skin epithelial barrier. Immunity. 2019;50:552–565. doi:10.1016/j.immuni.2019.02.023.
4. Matejuk A. Skin immunity. Arch Immunol Ther Exp (Warsz). 2018;66:45–54. doi:10.1007/s00005-017-0477-3
5. Sánchez-Pellicer P, Navarro-Moratalla L, Núñez-Delegido E, Ruzafa-Costas B, Agüera-Santos J, Navarro-López V. Acne, microbiome, and probiotics: the gut-skin axis. Microorganisms. 2022;10(7):1303. doi:10.3390/microorganisms10071303.
6. Zákostelská Z, Málková J, Klimešová K, Rossmann P, Hornová M, Novosádová I, Stehlíková Z, Kostovčík M, Hudcovic T, Štepánková R. Intestinal microbiota promotes psoriasis-like skin inflammation by enhancing Th17 response. PLoS One. 2016;11:e0159539. doi:10.1371/journal.pone.0159539.
7. Stehlikova Z, Kostovcikova K, Kverka M, Rossmann P, Dvorak J, Novosadova I, Kostovcik M, Coufal S, Srutkova D, Prochazkova P. Crucial role of microbiota in experimental psoriasis revealed by a gnotobiotic mouse model. Front Microbiol. 2019;10:236. doi:10.3389/fmicb.2019.00236.
8. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25(6):606–615. doi:10.1016/j.clindermatol.2007.08.015.
9. Kim HJ, Lee SH, Hong SJ. Antibiotics-induced dysbiosis of intestinal microbiota aggravates atopic dermatitis in mice by altered short-chain fatty acids. Allergy Asthma Immunol Res. 2020;12(1):137–148. doi:10.4168/aair.2020.12.1.137.
10. Polkowska-Pruszyńska B, Gerkowicz A, Krasowska D. The gut microbiome alterations in allergic and inflammatory skin diseases—an update. J Eur Acad Dermatol Venereol. 2020;34(3):455–464. doi:10.1111/jdv.15951.
11. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, de Paula JA, et al. World gastroenterology organisation global guidelines. J Clin Gastroenterol. 2012;46(6):468–481. doi:10.1097/mcg.0b013e3182549092.
12. Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the role of the gut microbiome and microbial metabolites in obesity and obesity-associated metabolic disorders: Current evidence and perspectives. Curr Obes Rep. 2019;8:317–332. doi:10.1007/s13679-019-00352-2
13. Scher JU, Littman DR, Abramson SB. Microbiome in inflammatory arthritis and human rheumatic diseases. Arthritis Rheumatol. 2016;68:35. doi:10.1002/art.39259.
14. Stevens BR, Roesch L, Thiago P, Russell JT, Pepine CJ, Holbert RC, Raizada MK, Triplett EW. Depression phenotype identified by using single nucleotide exact amplicon sequence variants of the human gut microbiome. Mol Psychiatry. 2021;26:4277–4287. doi:10.1038/s41380-020-0652-5.
15. Kitai T, Tang WW. Gut microbiota in cardiovascular disease and heart failure. Clin Sci. 2018;132:85–91. doi:10.1042/CS20171090.
16. Edpuganti, S., Thomas, K., Puthooran, D., & Mesineni, S. (2025). Gut Microbiome Dysbiosis in Autoimmune Diseases: Mechanisms, Biomarkers, and Therapeutic Strategies. International Journal of Progressive Sciences and Technologies, 49(2), 546-557. doi:http://dx.doi.org/10.52155/ijpsat.v49.2.7105
17. Fang J, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH, Yu WY. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018. doi:10.3389/fcimb.2022.997018.
18. Vitetta L. Letter on "Role of gut microbiome in immune regulation and immune checkpoint therapy of colorectal cancer". Med Oncol. 2023;40(5):143. doi:10.1007/s12032-023-02006-9.
19. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135. doi:10.1038/s41392-022-00974-4.
20. Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Protein Cell. 2021;12(5):360–373. doi:10.1007/s13238-020-00814-7.
21. Belvoncikova P, Maronek M, Gardlik R. Gut dysbiosis and fecal microbiota transplantation in autoimmune diseases. Int J Mol Sci. 2022;23(18):10729. doi:10.3390/ijms231810729.
22. Chang SH, Choi Y. Gut dysbiosis in autoimmune diseases: Association with mortality. Front Cell Infect Microbiol. 2023;13:1157918. doi:10.3389/fcimb.2023.1157918.
23. Mousa WK, Chehadeh F, Husband S. Microbial dysbiosis in the gut drives systemic autoimmune diseases. Front Immunol. 2022;13:906258. doi:10.3389/fimmu.2022.906258.
24. Wang X, Yuan W, Yang C, Wang Z, Zhang J, Xu D, Sun X, Sun W. Emerging role of gut microbiota in autoimmune diseases. Front Immunol. 2024;15:1365554. doi:10.3389/fimmu.2024.1365554.
25. Yao K, Xie Y, Wang J, Lin Y, Chen X, Zhou T. Gut microbiota: a newly identified environmental factor in systemic lupus erythematosus. Front Immunol. 2023;14:1202850. doi:10.3389/fimmu.2023.1202850.
26. Christovich A, Luo XM. Gut microbiota, leaky gut, and autoimmune diseases. Front Immunol. 2022;13:946248. doi:10.3389/fimmu.2022.946248.
27. Gobbo MM, Bomfim MB, Alves WY, Oliveira KC, Corsetti PP, de Almeida LA. Antibiotic-induced gut dysbiosis and autoimmune disease: A systematic review of preclinical studies. Autoimmun Rev. 2022;21(9):103140. doi:10.1016/j.autrev.2022.103140.
28. Maślińska M, Trędzbor B, Krzystanek M. Dysbiosis, gut-blood barrier rupture and autoimmune response in rheumatoid arthritis and schizophrenia. Reumatologia. 2021;59(3):180–187. doi:10.5114/reum.2021.107588.
29. Zhao T, Wei Y, Zhu Y, Xie Z, Hai Q, Li Z, Qin D. Gut microbiota and rheumatoid arthritis: From pathogenesis to novel therapeutic opportunities. Front Immunol. 2022;13:1007165. doi:10.3389/fimmu.2022.1007165.
30. Yoo JY, Groer M, Dutra SVO, Sarkar A, McSkimming DI. Gut microbiota and immune system interactions. Microorganisms. 2020;8(10):1587. doi:10.3390/microorganisms8101587.
31. Kujawa D, Laczmanski L, Budrewicz S, Pokryszko-Dragan A, Podbielska M. Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis. Gut Microbes. 2023;15(2):2274126. doi:10.1080/19490976.2023.2274126.
32. Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67(1):128–139. doi:10.1002/art.38892.
33. Eppinga H, Sperna Weiland CJ, Thio HB, van der Woude CJ, Nijsten TE, Peppelenbosch MP, Konstantinov SR. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016;10(9):1067–1075. doi:10.1093/ecco-jcc/jjw070.
34. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–573. doi:10.1126/science.1241165.
35. Hevia A, Milani C, López P, Cuervo A, Arboleya S, Duranti S, et al. Intestinal dysbiosis associated with systemic lupus erythematosus. mBio. 2014;5(5):e01548-14. doi:10.1128/mBio.01548-14.
36. De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019;195(1):74–85. doi:10.1111/cei.13158.
37. Moreno-Arrones OM, Serrano-Villar S, Perez-Brocal V, Saceda-Corralo D, Morales-Raya C, Rodrigues-Barata R, et al. Analysis of the gut microbiota in alopecia areata: identification of bacterial biomarkers. J Eur Acad Dermatol Venereol. 2020;34(2):400–405. doi:10.1111/jdv.15885.
38. Andréasson K, Alrawi Z, Persson A, Jönsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18(1):278. doi:10.1186/s13075-016-1182-z.
39. Buhaș MC, Candrea R, Gavrilaș LI, Miere D, Tătaru A, Boca A, Cătinean A. Transforming psoriasis care: Probiotics and prebiotics as novel therapeutic approaches. Int J Mol Sci. 2023;24(13):11225. doi:10.3390/ijms241311225.
40. [40]  Huang C, Yi P, Zhu M, Zhou W, Zhang B, Yi X, et al. Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial. J Autoimmun. 2022;130:102844. doi:10.1016/j.jaut.2022.102844.
41. Pinto D, Sorbellini E, Marzani B, Rucco M, Giuliani G, Rinaldi F. Scalp bacterial shift in alopecia areata. PLoS One. 2019;14(4):e0215206. doi:10.1371/journal.pone.0215206.
42. Edpuganti S, Gaikwad JR, Maliyil B, Koshy R, Potdar R, Latheef S, et al. The not-so-sweet side of mango: Mango allergy. CosmoDerma. 2025;5:18. doi:10.25259/CSDM_212_2024.
43. O’Neill CA, Monteleone G, McLaughlin JT, Paus R. The gut-skin axis in health and disease: A paradigm with therapeutic implications. BioEssays. 2016;38(11):1167–1176. doi:10.1002/bies.201600008.
44. Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167(4):1125–1136.e8. doi:10.1016/j.cell.2016.10.020.
45. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535(7610):75–84. doi:10.1038/nature18848.
46. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol. 2008;9(9):981–987. doi:10.1038/ni.f.208.
47. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and pathology. Eur J Immunol. 2017;47(4):607–614. doi:10.1002/eji.201646723.
48. Macia L, Tan J, Vieira AT, Leach K, Stanley D, Luong S, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat Commun. 2015;6:6734. doi:10.1038/ncomms7734.
49. Tanoue T, Atarashi K, Honda K. Development and maintenance of intestinal regulatory T cells. Nat Rev Immunol. 2016;16(5):295–309. doi:10.1038/nri.2016.36.
50. Chakraborty P, Banerjee D, Majumder P, Sarkar J. Gut microbiota nexus: Exploring the interactions with the brain, heart, lungs, and skin axes and their effects on health. Med Microecol. 2024;20:100104. doi:10.1016/j.medmic.2024.100104.
51. Liu X, Luo Y, Chen X, Wu M, Xu X, Tian J, et al. Fecal microbiota transplantation against moderate-to-severe atopic dermatitis: a randomized, double-blind controlled exploratory trial. Allergy. 2025;80(5):1377–1388. doi:10.1111/all.16372.
52. Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104(S2):S1–S63. doi:10.1017/S0007114510003363.
53. Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014;16(7):1024–1033. doi:10.1111/cmi.12308.
54. Edpuganti S, Shamim A, Gangolli VH, Weerasekara RADKN, Yellamilli A. Artificial Intelligence in Cardiovascular Imaging: Current Landscape, Clinical Impact, and Future Directions. Discoveries 2025, 13(2): e211. DOI: 10.15190/d.2025.10.